| |   | | | | By Allison DeAngelis Mike Reddy for STAT After raking in record amounts of capital over the last two years, VCs are seeing signs that the capital could dry up. Read More | | By Adam Feuerstein Sarah Silbiger/Getty Images The FDA’s decision to schedule a second advisory panel for the same drug is unusual, particularly during the same review period. Read More | | By Adam Feuerstein Ryan Pierse/Getty Images There's plenty to watch out for in the months ahead, including a readout from Alnylam Pharmaceuticals and another from Karuna Therapeutics. Read More | | Sponsor content by STAT+ Biopharma breakthroughs, business, and policy analysis — at your fingertips Enjoy daily, market-moving analysis of the biotech, pharma, and life sciences industries with STAT Plus. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. Don't be the last to know. Subscribe today to start reading. | | By Adam Feuerstein Jessica Rinaldi/The Boston Globe The company, based in Austin, Texas, believes its medicine could be used as a potential antidote for cannabis intoxication. Read More | |
No comments